Author： Johnson Julie A
Publisher： Future Medicine
ISSN： 1462-2416
Source： Pharmacogenomics, Vol.14, Iss.7, 2013-05, pp. : 835-843
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Hormone-Refractory Prostate Cancer: Where are We Going?
Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. :
Access to resources
Recommend
Progress in Colorectal Cancer Chemotherapy: How Far Have We Come, How Far to Go?
By Royce M.E.
Drugs & Aging, Vol. 17, Iss. 3, 2000-09 ,pp. :
Disease-Modifying Therapies in Alzheimer's Disease: How Far Have We Come?
By Hüll Michael Berger Mathias
Drugs, Vol. 66, Iss. 16, 2006-01 ,pp. :
'Atypical' antipsychotics: how far have we come?
Trends in Pharmacological Sciences, Vol. 22, Iss. 1, 2001-01 ,pp. :
Where are we going with ulcerative colitis management?
By Odes Selwyn
Expert Opinion on Emerging Drugs, Vol. 18, Iss. 1, 2013-03 ,pp. :